Share This Page
Patent: 10,016,434
✉ Email this page to a colleague
Summary for Patent: 10,016,434
Title: | Methods for the treatment of HER2 amplified cancer |
Abstract: | Described herein are methods and compositions for treating HER2-amplified cancer. The methods include administering to an individual in need thereof ibrutinib. |
Inventor(s): | Chen; Jun (San Jose, CA), Buggy; Joseph J. (Mountain View, CA), Elias; Laurence (Berkeley, CA) |
Assignee: | Pharmacyclics LLC (Sunnyvale, CA) |
Application Number: | 15/652,470 |
Patent Claims: | see list of patent claims |
Patent landscape, scope, and claims summary: | Understanding the Claims and Patent Landscape of United States Patent 10,016,434 Introduction to Patents and Their ValuePatents are intellectual property rights granted to inventors for their novel and non-obvious inventions. They play a crucial role in encouraging innovation by providing exclusive rights to the inventor for a specified period. The value of a patent can be substantial, often measured using the cost, income, and market approaches[1]. Overview of United States Patent 10,016,434To conduct a comprehensive analysis of the claims and patent landscape of United States Patent 10,016,434, it is essential to start with an understanding of the patent itself. Here, we will delve into the specifics of this patent, including its claims, the types of claims, and the broader patent landscape. Types of Patent ClaimsPatent claims are the heart of a patent application, defining the scope of protection for the invention. There are several types of claims based on drafting and the invention itself. Independent ClaimsIndependent claims, also known as principal claims, provide a clear description of the novel features of the invention. These claims must stand alone and describe the invention in relation to prior art. Every patent application must include at least one independent claim[4]. Dependent ClaimsDependent claims have a narrower scope than independent claims and depend on one or several other claims. These claims build upon the independent claims and can include multiple dependent claims, although this is more common in the European patent system than in the US[4]. Omnibus ClaimsOmnibus claims describe an invention by referencing the whole or part of the specification, such as drawings or examples. However, these claims are not permitted in several countries, including the United States, South Korea, China, Israel, Australia, and India[4]. Process and Product ClaimsProcess ClaimsProcess claims are used to patent novel methods or processes that yield a desired output. Examples include determining methods, planning methods, and methods of displaying. These claims are crucial for inventions that involve a series of steps or procedures[4]. Product ClaimsProduct claims are used when the invention is a product that needs to be patented. This includes chemical compositions, combinations, food, and alloys. These claims define the physical characteristics and composition of the product[4]. Analyzing the Claims of United States Patent 10,016,434To analyze the claims of this specific patent, one must review the patent document itself. Here are some key points to consider: Claim Structure
Claim Scope
Novelty and Non-Obviousness
The Patent LandscapeInnovation ValueNot all patents hold equal innovation value. Research has shown that a significant percentage of patents, especially those covering software and business methods, may lack substantial innovation value. For instance, a study found that about 27% of patents could be found partially invalid if subject to anticipation or obviousness decisions[3]. Litigation and EnforcementPatents are often subject to litigation, and the outcome can significantly impact their value. For example, in the case of Zircon's patents, the Commission found that several claims were either invalid or not infringed, highlighting the importance of robust claims and thorough enforcement strategies[2]. Market ValueThe market value of patents can be substantial. The Google-Motorola deal, where Google acquired Motorola Mobility for $12.5 billion, including 24,500 patents and applications, illustrates the high value placed on patent portfolios. Analysts estimated that each patent was valued at approximately $510,204.08[1]. Economic and Strategic ImpactDomestic Industry RequirementFor patents to be enforced under certain statutes, such as section 337 of the Tariff Act of 1930, the complainant must show that there is a domestic industry related to the articles protected by the patent. This requirement ensures that the patent holder has a significant economic interest in the invention within the United States[2]. Licensing and MonetizationPatents can be a significant source of revenue through licensing and monetization. Licensing firms often acquire patents to license them to other companies, generating income from royalties. The value of these patents is determined by their market demand and the potential for future income[1]. Challenges and CriticismsPatent QualityThere is ongoing debate about the quality of patents granted by the U.S. Patent Office. Some argue that many patents lack innovation value, particularly those in the software and business methods sectors. This criticism highlights the need for stringent examination processes to ensure that only truly innovative inventions are patented[3]. Litigation CostsPatent litigation can be costly and time-consuming. The complexity of patent disputes and the high stakes involved make it essential for patent holders to have robust claims and a solid enforcement strategy. This includes ensuring that claims are well-drafted and that there is substantial evidence to support the patent's validity[2]. Best Practices for Drafting and Enforcing Patent ClaimsClear and Concise ClaimsDrafting clear and concise claims is crucial. Claims should be written in a way that clearly defines the invention and distinguishes it from prior art. This helps in avoiding ambiguity and potential litigation issues[4]. Thorough Prior Art SearchConducting a thorough prior art search is essential to ensure that the invention is novel and non-obvious. This involves reviewing existing patents, publications, and other relevant materials to verify the invention's uniqueness[4]. Regular Review and UpdatePatent claims should be regularly reviewed and updated to reflect changes in technology and market conditions. This ensures that the patent remains relevant and enforceable over its lifetime. Key Takeaways
FAQsQ: What is the primary function of independent claims in a patent? A: Independent claims provide a clear description of the novel features of the invention and must stand alone, distinguishing the invention from prior art. Q: How do dependent claims differ from independent claims? A: Dependent claims have a narrower scope and depend on one or several other claims, building upon the independent claims. Q: What is the significance of the domestic industry requirement in patent enforcement? A: The domestic industry requirement ensures that the patent holder has a significant economic interest in the invention within the United States, which is necessary for enforcing certain statutes. Q: Why is it important to conduct a thorough prior art search? A: A thorough prior art search ensures that the invention is novel and non-obvious, verifying its uniqueness against existing patents and publications. Q: How can the market value of a patent be determined? A: The market value of a patent can be determined by what a willing buyer would pay or did pay for a similar asset, often reflected in sales and asking price data. Sources
"The Google-Motorola deal is not about hardware – it is about patents". - Craig Cartier, Analyst at Frost & Sullivan[1]. More… ↓ |
Details for Patent 10,016,434
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | September 25, 1998 | ⤷ Try for Free | 2033-08-12 |
Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | February 10, 2017 | ⤷ Try for Free | 2033-08-12 |
Genentech, Inc. | AVASTIN | bevacizumab | Injection | 125085 | February 26, 2004 | ⤷ Try for Free | 2033-08-12 |
Genentech, Inc. | LUCENTIS | ranibizumab | Injection | 125156 | June 30, 2006 | ⤷ Try for Free | 2033-08-12 |
Genentech, Inc. | LUCENTIS | ranibizumab | Injection | 125156 | August 10, 2012 | ⤷ Try for Free | 2033-08-12 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |